Natixis Advisors LLC Has $12.68 Million Stock Position in Penumbra, Inc. $PEN

Natixis Advisors LLC increased its position in shares of Penumbra, Inc. (NYSE:PEN) by 4.1% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 40,772 shares of the company’s stock after purchasing an additional 1,593 shares during the quarter. Natixis Advisors LLC owned approximately 0.10% of Penumbra worth $12,676,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in PEN. Larson Financial Group LLC increased its position in shares of Penumbra by 4,100.0% during the 4th quarter. Larson Financial Group LLC now owns 84 shares of the company’s stock worth $26,000 after purchasing an additional 82 shares in the last quarter. Morse Asset Management Inc acquired a new stake in Penumbra in the 4th quarter valued at about $39,000. Rothschild Investment LLC acquired a new stake in Penumbra in the 3rd quarter valued at about $40,000. Farther Finance Advisors LLC increased its position in Penumbra by 27.1% in the 4th quarter. Farther Finance Advisors LLC now owns 178 shares of the company’s stock valued at $55,000 after acquiring an additional 38 shares in the last quarter. Finally, Allworth Financial LP increased its position in Penumbra by 36.2% in the 3rd quarter. Allworth Financial LP now owns 241 shares of the company’s stock valued at $61,000 after acquiring an additional 64 shares in the last quarter. Institutional investors and hedge funds own 88.88% of the company’s stock.

Insider Activity at Penumbra

In other news, Director Harpreet Grewal sold 100 shares of Penumbra stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $328.22, for a total transaction of $32,822.00. Following the completion of the sale, the director owned 8,719 shares in the company, valued at $2,861,750.18. The trade was a 1.13% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.90% of the stock is currently owned by corporate insiders.

Penumbra Stock Down 0.0%

Shares of NYSE:PEN opened at $320.51 on Friday. Penumbra, Inc. has a one year low of $221.26 and a one year high of $362.41. The company has a 50 day moving average of $326.86 and a 200-day moving average of $326.01. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.02 and a quick ratio of 3.95. The stock has a market cap of $12.61 billion, a price-to-earnings ratio of 73.85, a P/E/G ratio of 1.96 and a beta of 0.71.

Penumbra (NYSE:PEN) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.82 EPS for the quarter, missing the consensus estimate of $1.06 by ($0.24). Penumbra had a return on equity of 10.87% and a net margin of 11.76%.The business had revenue of $374.76 million for the quarter, compared to analyst estimates of $370.47 million. During the same quarter in the prior year, the firm earned $0.83 EPS. The firm’s quarterly revenue was up 15.6% compared to the same quarter last year. On average, sell-side analysts forecast that Penumbra, Inc. will post 5.08 earnings per share for the current year.

Analyst Upgrades and Downgrades

PEN has been the subject of several research reports. Wall Street Zen upgraded shares of Penumbra to a “hold” rating in a research report on Saturday, May 9th. Citigroup lowered their price objective on shares of Penumbra from $374.00 to $350.00 and set a “neutral” rating for the company in a research report on Thursday, May 7th. UBS Group restated a “neutral” rating and issued a $374.00 price objective on shares of Penumbra in a research report on Thursday, February 26th. Finally, Evercore restated an “outperform” rating and issued a $335.00 price objective on shares of Penumbra in a research report on Thursday, May 7th. Three analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Penumbra presently has a consensus rating of “Hold” and a consensus price target of $361.33.

About Penumbra

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.